Standard BioTools Announces Exchange of Series B Convertible Preferred Stock for Common Stock
SOUTH SAN FRANCISCO, Calif. March 18, 2024 - Standard BioTools Inc.(Nasdaq: LAB) made an announcement today regarding the exchange of all outstanding shares of its Series B Convertible Preferred Stock for common stock.This exchange was made possible through an agreement with stockholders affiliated with Viking Global Investors and Casdin Capital.
As a result of this exchange, Standard BioTools Inc.had 79.152 million shares outstanding, with the current price sitting at $2.62.This move signifies a strategic decision by the company to streamline its capital structure and align its stock ownership with its long-term goals.
Investors and stakeholders can expect to see increased liquidity and improved shareholder value as a result of this exchange.Standard BioTools Inc.remains committed to driving innovation in the biotechnology sector and delivering value to its shareholders.
Comments